pfizer
How will Pfizer's discounted biosimilars affect Roche?
February 7, 2020 by Global Pricing Innovations (GPI)
Pfizer’s newest range of biosimilars are set to significantly undercut Roche’s ‘best-selling’ Avastin, Herceptin, and Rituxan on pricing. What will be the impact on Roche’s market share?

Pfizer has planned the launch of its biosimilar competitors in the U.S. to Roche’s cancer drugs, Avastin, Herceptin, and Rituxan, at significantly discounted prices, in comparison to the originators. Experts have noted that the launch of these medicines can lead to substantial savings…

June 3, 2019 by Global Pricing Innovations (GPI)
Prices of Pfizer’s leukaemia drug Bosulif cut by 13% in Germany after HTA

  The retail prices of Pfizer’s leukaemia drug Bosulif (bosutinib) were cut by 13% in Germany on 1 June. This is likely a result of recent price negotiations with GKV-Spitzenverband payer group. Per AMNOG procedure, the negotiations were triggered by Bosulif losing its…